Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman; Edward F. McKone; D.G. Downey; Eva Van Braeckel; Steven M. Rowe; Elizabeth Tullis; Marcus Mall; John Welter; Bonnie W. Ramsey; Charlotte McKee; Gautham Marigowda; Samuel M. Moskowitz; David Waltz; Patrick R. Sosnay; C Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L. Taylor‐Cousar; Karen McCoy; Karen McCoy; Scott H. Donaldson; Seth Walker; James F. Chmiel; Ronald C. Rubenstein; Deborah Froh; Isabel P. Neuringer; Manu Jain; Kathryn Moffett; Jennifer L. Taylor‐Cousar; Bruce Barnett; Gary A. Mueller; Patrick A. Flume; F. R. Livingston; Nighat Mehdi; Charlotte C. Tenebäck; John Welter; Raksha Jain; Dana G. Kissner; K. Patel; Francisco J. Calimano; Jimmy Johannes; Cori Daines; Thomas G. Keens; Herschel Scher; Subramanyam Chittivelu; Sudhakar Reddivalam; Ross C. Klingsberg; Larry G. Johnson; Stijn Verhulst; Patricia Macedo; D.G. Downey; Gary Connett; E.F. Nash; Nicholas Withers; Timothy Lee; Marleen Bakker; Harry Heijerman; F. Vermeulen; Eva Van Braeckel; Christiane Knoop; Elke De Wachter; Eva Van Braeckel; Petrus Merkus; Christof J. Majoor

doi:10.1016/s0140-6736(19)32597-8

Keywords

IvacaftorCystic fibrosisRegimenMedicineDouble blindInternal medicineMutationClinical trialGeneticsAlternative medicinePathologyBiologyCystic fibrosis transmembrane conductance regulatorPlacebo

Affiliated Institutions

Related Publications

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton , Marcus Mall , Pavel Dřevı́nek +18 more

Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffe...

2019 New England Journal of Medicine 1929 citations

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Thierry Poynard , Patrick Marcellin , Samuel S. Lee +8 more

Only 15-20% of patients with chronic hepatitis C achieve a sustained virological response with interferon therapy. The aim of this study was to compare the efficacy and safety o...

1998 The Lancet 2330 citations

Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping

Emanuele Buratti , Thilo Dörk , Elisabetta Zuccato +3 more

Alternative splicing of human cystic fibrosis transmembrane conductance regulator (CFTR) exon 9 is regulated by a combination of cis-acting elements distributed through the exon...

2001 The EMBO Journal 619 citations

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet , Florian Castet , Mathias Heikenwälder +6 more

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patie...

2021 Nature Reviews Clinical Oncology 1590 citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann , D. Quietzsch , Frank Gieseler +17 more

Purpose To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic p...

2006 Journal of Clinical Oncology 682 citations

Publication Info

Year: 2019
Type: article
Volume: 394
Issue: 10212
Pages: 1940-1948
Citations: 1270
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1270

OpenAlex

Cite This

APA Style

                            
                                
                                    Harry Heijerman, 
                                
                                    Edward F. McKone, 
                                
                                    D.G. Downey
                                
                                et al.
                            
                            (2019). 
                            Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. 
                            The Lancet
                            , 394
                            (10212)
                            , 1940-1948.
                            https://doi.org/10.1016/s0140-6736(19)32597-8
                        

Identifiers

DOI: 10.1016/s0140-6736(19)32597-8